LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

LLY

769.87

+0.76%↑

JNJ

155.03

+1.03%↑

ABBV

189.89

+1.42%↑

NVO

74.74

+3.06%↑

UNH

303.11

+2.59%↑

Search

Blueprint Medicines Corp

Fermé

SecteurSoins de santé

127.83 -0.02

Résumé

Variation du prix de l'action

24h

Actuel

Min

127.51

Max

128.01

Chiffres clés

By Trading Economics

Revenu

50M

496K

Ventes

3M

149M

BPA

-0.294

Marge bénéficiaire

0.332

Employés

682

EBITDA

-14M

-41M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+1.35% upside

Dividendes

By Dow Jones

Prochains Résultats

31 juil. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

2.5B

8.3B

Ouverture précédente

127.85

Clôture précédente

127.83

Sentiment de l'Actualité

By Acuity

32%

68%

87 / 380 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Bullish Evidence

Blueprint Medicines Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

2 juin 2025, 09:17 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Blueprint Medicines for Up to $9.5 Billion in Boost to Pipeline -- Update

2 juin 2025, 05:31 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Blueprint Medicines for Up to $9.5 Billion

2 juin 2025, 13:50 UTC

Résultats
Acquisitions, Fusions, Rachats

Blueprint Medicines Soars 26% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 juin 2025, 10:50 UTC

Acquisitions, Fusions, Rachats

Blueprint Medicines Soars 27% on $9.5 Billion Buyout. Why This Drug Is Key to the Deal. -- Barrons.com

2 juin 2025, 10:05 UTC

Market Talk
Acquisitions, Fusions, Rachats

Sanofi's Blueprint Deal Seems Like Good Fit -- Market Talk

2 juin 2025, 05:06 UTC

Acquisitions, Fusions, Rachats

Sanofi: Total Equity Value, Including Potential CVR Payments, Represents About $9.5B on Fully Diluted Basis

2 juin 2025, 05:06 UTC

Acquisitions, Fusions, Rachats

Sanofi: Blueprint Shareholders Also Will Receive One Non-Tradeable Contingent Value Right

2 juin 2025, 05:05 UTC

Acquisitions, Fusions, Rachats

Sanofi: Deal Represents an Equity Value of Approximately $9.1B

2 juin 2025, 05:05 UTC

Acquisitions, Fusions, Rachats

Sanofi Will Pay $129.00 Per Share in Cash at Closing

2 juin 2025, 05:04 UTC

Acquisitions, Fusions, Rachats

Sanofi: Blueprint Is Expected to Enhance Sanofi's Growing Immunology Pipeline

2 juin 2025, 05:04 UTC

Acquisitions, Fusions, Rachats

Sanofi: Acquisition Includes Rare Immunology Disease Medicine, Ayvakit/Ayvakyt

2 juin 2025, 05:03 UTC

Acquisitions, Fusions, Rachats

Sanofi to Buy Blueprint Medicines Corporation

2 juin 2025, 05:02 UTC

Acquisitions, Fusions, Rachats

Sanofi to Acquire Blueprint Medicines Corporation

Comparaison

Variation de prix

Blueprint Medicines Corp prévision

Objectif de Prix

By TipRanks

1.35% hausse

Prévisions sur 12 Mois

Moyen 129.63 USD  1.35%

Haut 143 USD

Bas 105 USD

Basé sur 20 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

20 ratings

4

Achat

16

Maintien

0

Vente

Score Technique

By Trading Central

87.66 / 99.25Support & Résistance

Court Terme

Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bullish Evidence

Sentiment

By Acuity

87 / 380Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Blueprint Medicines Corp

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medullary thyroid carcinoma; BLU-945 for the treatment of epidermal growth factor receptor driven non-small-cell lung carcinoma (NSCLC); and BLU-451 to treat NSCLC in patients with epidermal growth factor receptor gene (EGFR) exon 20 insertion mutations. In addition, the company is developing BLU-782, for the treatment of fibrodysplasia ossificans progressive; BLU- 222 to treat patients with cyclin E aberrant cancers; and BLU-852 for the treatment of advanced cancers. It has collaboration and license agreements with Clementia Pharmaceuticals, Inc.; Proteovant Therapeutics; CStone Pharmaceuticals; Genentech, Inc.; Hoffmann-La Roche Inc.; and Zai Lab (Shanghai) Co., Ltd. The company was formerly known as Hoyle Pharmaceuticals, Inc. and changed its name to Blueprint Medicines Corporation in June 2011. Blueprint Medicines Corporation was incorporated in 2008 and is headquartered in Cambridge, Massachusetts.